Optimal Duration of Adjuvant Therapy for Patients With Resected Gastrointestinal Stromal Tumors

Blanke talks about the study by Joensu et al that report the results of Scandinavian Group SSGXVIII trial, a randomized phase 3 trial comparing 12 vs. 36 months of adjuvant imatinib (400 mg per day), administered following tumor resection to patients deemed to be at high risk for gastrointestinal st...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	JAMA : the journal of the American Medical Association 2012-03, Vol.307 (12), p.1312-1314
1. Verfasser:	Blanke, Charles D
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - administration & dosage Benzamides Clinical trials Female Gastrointestinal diseases Gastrointestinal Neoplasms - drug therapy Gastrointestinal Stromal Tumors - drug therapy Humans Imatinib Mesylate Male Piperazines - administration & dosage Pyrimidines - administration & dosage Therapy Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!